JP2008537547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008537547A5 JP2008537547A5 JP2008502896A JP2008502896A JP2008537547A5 JP 2008537547 A5 JP2008537547 A5 JP 2008537547A5 JP 2008502896 A JP2008502896 A JP 2008502896A JP 2008502896 A JP2008502896 A JP 2008502896A JP 2008537547 A5 JP2008537547 A5 JP 2008537547A5
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- phenyl
- methyl
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 51
- 239000001257 hydrogen Substances 0.000 claims 51
- -1 phenylsulfonylamino Chemical group 0.000 claims 49
- 150000002431 hydrogen Chemical class 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 18
- 125000001153 fluoro group Chemical group F* 0.000 claims 15
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 15
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 10
- 125000004414 alkyl thio group Chemical group 0.000 claims 10
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 8
- 125000001246 bromo group Chemical group Br* 0.000 claims 8
- 125000002346 iodo group Chemical group I* 0.000 claims 8
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 3
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 3
- YPDOLVWKPFGIBB-QGZVFWFLSA-N 3-(4-tert-butylphenyl)-n-[(1r)-1-[4-(methanesulfonamido)phenyl]ethyl]-2-methylprop-2-enamide Chemical compound N([C@H](C)C=1C=CC(NS(C)(=O)=O)=CC=1)C(=O)C(C)=CC1=CC=C(C(C)(C)C)C=C1 YPDOLVWKPFGIBB-QGZVFWFLSA-N 0.000 claims 2
- WCGYTMNVBCVJLH-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[3-fluoro-4-(methanesulfonamido)phenyl]methyl]-2-methylprop-2-enamide Chemical compound C=1C=C(NS(C)(=O)=O)C(F)=CC=1CNC(=O)C(C)=CC1=CC=C(C(C)(C)C)C=C1 WCGYTMNVBCVJLH-UHFFFAOYSA-N 0.000 claims 2
- XCWKFLJPCLZFPY-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[3-fluoro-4-(methanesulfonamido)phenyl]methyl]but-2-enamide Chemical compound C=1C=C(C(C)(C)C)C=CC=1C(C)=CC(=O)NCC1=CC=C(NS(C)(=O)=O)C(F)=C1 XCWKFLJPCLZFPY-UHFFFAOYSA-N 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- ZDOJKAWETLKRAR-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)C Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)C ZDOJKAWETLKRAR-UHFFFAOYSA-N 0.000 claims 2
- MVQZGMUKEVRCRJ-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1C)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)Cl Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1C)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)Cl MVQZGMUKEVRCRJ-UHFFFAOYSA-N 0.000 claims 2
- IPPITQAIEDIDAN-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1F)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)CC Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1F)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)CC IPPITQAIEDIDAN-UHFFFAOYSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 102000011040 TRPV Cation Channels Human genes 0.000 claims 2
- 108010062740 TRPV Cation Channels Proteins 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 2
- FSYKSFRXUZLDLC-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[1-[3-fluoro-4-(methanesulfonamido)phenyl]ethyl]-2-methylprop-2-enamide Chemical compound C=1C=C(NS(C)(=O)=O)C(F)=CC=1C(C)NC(=O)C(C)=CC1=CC=C(C(C)(C)C)C=C1 FSYKSFRXUZLDLC-UHFFFAOYSA-N 0.000 claims 1
- SAXIEWTXPPNTPQ-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[2,5-difluoro-4-(methanesulfonamido)phenyl]methyl]prop-2-enamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C=CC(=O)NCC1=CC(F)=C(NS(C)(=O)=O)C=C1F SAXIEWTXPPNTPQ-UHFFFAOYSA-N 0.000 claims 1
- XSUQVHTVTDENPS-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[3-fluoro-4-(methanesulfonamido)-5-methylphenyl]methyl]prop-2-enamide Chemical compound FC1=C(NS(C)(=O)=O)C(C)=CC(CNC(=O)C=CC=2C=CC(=CC=2)C(C)(C)C)=C1 XSUQVHTVTDENPS-UHFFFAOYSA-N 0.000 claims 1
- KVWPNZFSUHALEX-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[4-(methanesulfonamido)-3-methylphenyl]methyl]prop-2-enamide Chemical compound C1=C(NS(C)(=O)=O)C(C)=CC(CNC(=O)C=CC=2C=CC(=CC=2)C(C)(C)C)=C1 KVWPNZFSUHALEX-UHFFFAOYSA-N 0.000 claims 1
- GOPCVYDNMNVXLB-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-[[4-(methanesulfonamido)phenyl]methyl]-2-methylprop-2-enamide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CNC(=O)C(C)=CC1=CC=C(C(C)(C)C)C=C1 GOPCVYDNMNVXLB-UHFFFAOYSA-N 0.000 claims 1
- MKZOQDDEBSOPHS-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=C(C=C(C(=C2)I)NS(=O)(=O)C)Cl Chemical compound CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=C(C=C(C(=C2)I)NS(=O)(=O)C)Cl MKZOQDDEBSOPHS-UHFFFAOYSA-N 0.000 claims 1
- HFONNRJJPMYDHW-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=CC(=C(C(=C2)I)NS(=O)(=O)C)F Chemical compound CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=CC(=C(C(=C2)I)NS(=O)(=O)C)F HFONNRJJPMYDHW-UHFFFAOYSA-N 0.000 claims 1
- CUDYMAHPCXNGGH-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=CC(=C(C=C2)NS(=O)(=O)C)[N+](=O)[O-] Chemical compound CC(C)(C)C1=CC=C(C=C1)CCNC(=O)NC2=CC(=C(C=C2)NS(=O)(=O)C)[N+](=O)[O-] CUDYMAHPCXNGGH-UHFFFAOYSA-N 0.000 claims 1
- CSRODXZWTLGCED-UHFFFAOYSA-N CC(C)(C)C1=CC=C(C=C1)CN(C)C(=O)NC2=CC(=C(C=C2F)NS(=O)(=O)C)F Chemical compound CC(C)(C)C1=CC=C(C=C1)CN(C)C(=O)NC2=CC(=C(C=C2F)NS(=O)(=O)C)F CSRODXZWTLGCED-UHFFFAOYSA-N 0.000 claims 1
- YXKHKFLLTRQGFW-UHFFFAOYSA-N CC(C=C(C)C(=O)N)C1=CC(=C(C=C1)NS(=O)(=O)C)F Chemical compound CC(C=C(C)C(=O)N)C1=CC(=C(C=C1)NS(=O)(=O)C)F YXKHKFLLTRQGFW-UHFFFAOYSA-N 0.000 claims 1
- RJQSGDYBJRGRGO-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C(=C1)Cl)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)CC Chemical compound CS(=O)(=O)NC1=C(C=C(C(=C1)Cl)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)CC RJQSGDYBJRGRGO-UHFFFAOYSA-N 0.000 claims 1
- NZMRNRBISIEWGR-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)N(CC1=CC=C(C=C1)C(C)(C)C)C)I Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)N(CC1=CC=C(C=C1)C(C)(C)C)C)I NZMRNRBISIEWGR-UHFFFAOYSA-N 0.000 claims 1
- UZPJCAWQGSECJM-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)Cl Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)Cl UZPJCAWQGSECJM-UHFFFAOYSA-N 0.000 claims 1
- YRSRONNGLWKBEN-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)F Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1)NC(=O)NCCC1=CC=C(C=C1)C(C)(C)C)F YRSRONNGLWKBEN-UHFFFAOYSA-N 0.000 claims 1
- ZQGAWNADNXEOET-UHFFFAOYSA-N CS(=O)(=O)NC1=C(C=C(C=C1F)NC(=O)N(CC1=CC=C(C=C1)C(C)(C)C)C)F Chemical compound CS(=O)(=O)NC1=C(C=C(C=C1F)NC(=O)N(CC1=CC=C(C=C1)C(C)(C)C)C)F ZQGAWNADNXEOET-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims 1
- 206010037083 Prurigo Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050022986 | 2005-03-19 | ||
| KR10-2005-0022986 | 2005-03-19 | ||
| US66326905P | 2005-03-21 | 2005-03-21 | |
| US60/663,269 | 2005-03-21 | ||
| PCT/KR2006/000988 WO2006101321A1 (en) | 2005-03-19 | 2006-03-17 | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008537547A JP2008537547A (ja) | 2008-09-18 |
| JP2008537547A5 true JP2008537547A5 (enExample) | 2009-04-16 |
| JP5064374B2 JP5064374B2 (ja) | 2012-10-31 |
Family
ID=37023953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502895A Expired - Fee Related JP5159604B2 (ja) | 2005-03-19 | 2006-03-15 | バニロイド受容体拮抗薬としての新規な化合物、その異性体又はその薬剤学的に許容される塩、及びこれを含む医薬組成物 |
| JP2008502896A Expired - Fee Related JP5064374B2 (ja) | 2005-03-19 | 2006-03-17 | バニロイド受容体拮抗薬としての新規な化合物、その異性体またはその薬剤学的に許容される塩、及びこれを含む医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502895A Expired - Fee Related JP5159604B2 (ja) | 2005-03-19 | 2006-03-15 | バニロイド受容体拮抗薬としての新規な化合物、その異性体又はその薬剤学的に許容される塩、及びこれを含む医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7763657B2 (enExample) |
| EP (2) | EP1861357B1 (enExample) |
| JP (2) | JP5159604B2 (enExample) |
| KR (2) | KR101304981B1 (enExample) |
| AR (2) | AR056943A1 (enExample) |
| AU (2) | AU2006225496A1 (enExample) |
| BR (2) | BRPI0608714A2 (enExample) |
| CA (2) | CA2601871A1 (enExample) |
| EA (2) | EA200702020A1 (enExample) |
| IL (2) | IL185891A0 (enExample) |
| MX (2) | MX2007011466A (enExample) |
| NO (2) | NO20075353L (enExample) |
| TW (2) | TW200716523A (enExample) |
| WO (2) | WO2006101318A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006225496A1 (en) * | 2005-03-19 | 2006-09-28 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| CA2658925C (en) | 2006-07-27 | 2015-07-14 | Amorepacific Corporation | Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2009023025A1 (en) * | 2007-08-13 | 2009-02-19 | Board Of Trustees Of Southern Illinois University | Methods for treatment and prevention of ototoxicity by sirna |
| WO2009096701A2 (en) | 2008-01-28 | 2009-08-06 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| EP2277861A4 (en) | 2008-05-07 | 2012-05-02 | Dainippon Sumitomo Pharma Co | CYCLIC AMIN-1-CARBOXYLIC ACID EST DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREWITH |
| JP5438103B2 (ja) | 2008-07-02 | 2014-03-12 | アモーレパシフィック コーポレイション | バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物 |
| ES2673301T3 (es) * | 2010-11-03 | 2018-06-21 | University Of Hawaii | Métodos y composiciones para la prevención y el tratamiento de la hipertrofia cardíaca |
| AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
| US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| PL2797416T3 (pl) | 2011-12-28 | 2017-12-29 | Global Blood Therapeutics, Inc. | Podstawione związki benzaldehydowe i sposoby ich zastosowania do zwiększania natlenienia tkanek |
| WO2014104272A1 (ja) * | 2012-12-28 | 2014-07-03 | 日本臓器製薬株式会社 | ケイ皮酸アミド誘導体 |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| AP2016009261A0 (en) | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| PL3383392T3 (pl) | 2015-12-04 | 2025-11-17 | Global Blood Therapeutics, Inc. | Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6087254A (ja) * | 1983-10-19 | 1985-05-16 | Japan Carlit Co Ltd:The | 新規尿素化合物及びそれを含有する除草剤 |
| EP1154989B1 (en) * | 1999-02-22 | 2005-12-14 | Pacific Corporation | Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof |
| NZ523882A (en) | 2000-08-21 | 2004-11-26 | Pacific Corp | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| EP1311478B1 (en) * | 2000-08-21 | 2006-06-07 | Pacific Corporation | Novel (thio)urea compounds and the pharmaceutical compositions containing the same |
| GB0105895D0 (en) * | 2001-03-09 | 2001-04-25 | Smithkline Beecham Plc | Novel compounds |
| MXPA04005427A (es) | 2001-12-10 | 2005-04-19 | Amgen Inc | Ligandos de receptor vainilloide y su uso en tratamientos. |
| EP1506167B1 (en) | 2002-05-08 | 2007-08-29 | Bayer HealthCare AG | Hydroxy tetrahydro-naphthalenylurea derivatives |
| US7183411B2 (en) * | 2002-07-12 | 2007-02-27 | Janssen Pharmaceutica N.V. | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor |
| KR100707123B1 (ko) * | 2003-07-02 | 2007-04-16 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물 |
| KR101042490B1 (ko) * | 2004-07-15 | 2011-06-16 | 니뽄 다바코 산교 가부시키가이샤 | 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제 |
| ITMI20042042A1 (it) * | 2004-10-26 | 2005-01-26 | Pharmeste Srl | Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1 |
| EP1858865B1 (en) * | 2005-03-10 | 2009-09-16 | Pfizer Inc. | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds |
| AU2006225496A1 (en) * | 2005-03-19 | 2006-09-28 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
-
2006
- 2006-03-15 AU AU2006225496A patent/AU2006225496A1/en not_active Abandoned
- 2006-03-15 CA CA002601871A patent/CA2601871A1/en not_active Abandoned
- 2006-03-15 EA EA200702020A patent/EA200702020A1/ru unknown
- 2006-03-15 WO PCT/KR2006/000929 patent/WO2006101318A1/en not_active Ceased
- 2006-03-15 BR BRPI0608714-0A patent/BRPI0608714A2/pt not_active Application Discontinuation
- 2006-03-15 MX MX2007011466A patent/MX2007011466A/es not_active Application Discontinuation
- 2006-03-15 US US11/909,136 patent/US7763657B2/en active Active
- 2006-03-15 JP JP2008502895A patent/JP5159604B2/ja not_active Expired - Fee Related
- 2006-03-15 EP EP06716379.0A patent/EP1861357B1/en not_active Expired - Lifetime
- 2006-03-15 KR KR1020077024002A patent/KR101304981B1/ko not_active Expired - Fee Related
- 2006-03-17 EP EP06716438A patent/EP1861358A4/en not_active Withdrawn
- 2006-03-17 TW TW095109337A patent/TW200716523A/zh unknown
- 2006-03-17 US US11/909,144 patent/US7960584B2/en active Active
- 2006-03-17 WO PCT/KR2006/000988 patent/WO2006101321A1/en not_active Ceased
- 2006-03-17 AR ARP060101058A patent/AR056943A1/es unknown
- 2006-03-17 AU AU2006225434A patent/AU2006225434A1/en not_active Abandoned
- 2006-03-17 CA CA002601873A patent/CA2601873A1/en not_active Abandoned
- 2006-03-17 MX MX2007011205A patent/MX2007011205A/es not_active Application Discontinuation
- 2006-03-17 BR BRPI0608624-1A patent/BRPI0608624A2/pt not_active Application Discontinuation
- 2006-03-17 EA EA200702021A patent/EA200702021A1/ru unknown
- 2006-03-17 AR ARP060101059A patent/AR053561A1/es unknown
- 2006-03-17 KR KR1020077024004A patent/KR101304979B1/ko not_active Expired - Fee Related
- 2006-03-17 JP JP2008502896A patent/JP5064374B2/ja not_active Expired - Fee Related
- 2006-03-17 TW TW095109137A patent/TW200716522A/zh unknown
-
2007
- 2007-09-11 IL IL185891A patent/IL185891A0/en unknown
- 2007-09-11 IL IL185892A patent/IL185892A0/en unknown
- 2007-10-18 NO NO20075353A patent/NO20075353L/no not_active Application Discontinuation
- 2007-10-18 NO NO20075354A patent/NO20075354L/no not_active Application Discontinuation